ATRI Stock Overview
Develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Atrion Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$471.99 |
| 52 Week High | US$602.59 |
| 52 Week Low | US$274.98 |
| Beta | 0.62 |
| 1 Month Change | 16.46% |
| 3 Month Change | 34.73% |
| 1 Year Change | -13.09% |
| 3 Year Change | -23.13% |
| 5 Year Change | -46.97% |
| Change since IPO | 1,839.69% |
Recent News & Updates
Recent updates
There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings
May 22
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Mar 24Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%
Mar 23Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly
Feb 09Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up
Jan 04Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly
Sep 14Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends
Jul 18Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital
Apr 19Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital
Oct 18Atrion: Attractively Priced For Exposure To Defensive Healthcare
Sep 08Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's
Aug 27Atrion raises dividend 10.3% to $2.15/share
Aug 22Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital
Jul 18Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital
Jan 03Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95
Nov 18Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95
Sep 03There Are Reasons To Feel Uneasy About Atrion's (NASDAQ:ATRI) Returns On Capital
Jul 09Here's Why Atrion Corporation's (NASDAQ:ATRI) CEO Compensation Is The Least Of Shareholders Concerns
May 15Atrion reports Q1 results
May 10Atrion Corporation (NASDAQ:ATRI) Is Yielding 1.1% - But Is It A Buy?
Apr 12Atrion Corporation (NASDAQ:ATRI) Pays A US$1.75 Dividend In Just Four Days
Mar 07Need To Know: Atrion Corporation (NASDAQ:ATRI) Insiders Have Been Buying Shares
Feb 26Should You Be Impressed By Atrion's (NASDAQ:ATRI) Returns on Capital?
Feb 11
Are Robust Financials Driving The Recent Rally In Atrion Corporation's (NASDAQ:ATRI) Stock?
Jan 27Atrion (NASDAQ:ATRI) Shareholders Have Enjoyed A 89% Share Price Gain
Jan 12Is Atrion Corporation (NASDAQ:ATRI) A Great Dividend Stock?
Dec 28Shareholder Returns
| ATRI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.5% | -0.2% | -0.2% |
| 1Y | -13.1% | 5.2% | 28.2% |
Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 5.2% over the past year.
Return vs Market: ATRI underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| ATRI volatility | |
|---|---|
| ATRI Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ATRI's share price has been volatile over the past 3 months.
Volatility Over Time: ATRI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 712 | David Battat | www.atrioncorp.com |
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company’s fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.
Atrion Corporation Fundamentals Summary
| ATRI fundamental statistics | |
|---|---|
| Market cap | US$830.68m |
| Earnings (TTM) | US$18.72m |
| Revenue (TTM) | US$176.67m |
44.4x
P/E Ratio4.7x
P/S RatioIs ATRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRI income statement (TTM) | |
|---|---|
| Revenue | US$176.67m |
| Cost of Revenue | US$114.71m |
| Gross Profit | US$61.96m |
| Other Expenses | US$43.24m |
| Earnings | US$18.72m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.64 |
| Gross Margin | 35.07% |
| Net Profit Margin | 10.60% |
| Debt/Equity Ratio | 0% |
How did ATRI perform over the long term?
See historical performance and comparison